Christopher Fuglesang

Dr. Fugelsang is a Co-Founder and Managing Director of Boxer Capital, LLC.

After joining Tavistock Group in 2005, Dr. Fuglesang helped scale Tavistock Group’s public healthcare investing activities with Boxer Capital. Dr. Fuglesang assists in managing the firm’s research team, deal structuring, and securities compliance.

Dr. Fuglesang is a Member of the Board of Directors of CiVi Biopharma, Inc., BCTG Acquisition Corporation (NASDAQ: BCTG) and previously served on Pandion Therapeutics (NASDAQ: PAND) before its acquisition by Merck.

Earlier in his career, Dr. Fuglesang supervised a variety of transactions, including mergers and acquisitions, joint ventures, and other strategic collaborations in the healthcare sector.

Dr. Fuglesang brings with him years of experience in building and developing life science companies, previously founding, and holding board and executive management positions at multiple biotechnology companies.

Dr. Fuglesang holds a Doctorate degree in Chemical Physics from the University of California, Los Angeles, a Juris Doctor degree from the Boston University School of Law, and Bachelor of Science degrees in Chemistry and Physics from the University of California, Los Angeles.